Related Experiment Video
Updated: Aug 11, 2026
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy
Thomas H Brannagan1, Armin Alaedini, Douglas E Gladstone
1Weill Medical College of Cornell University, Department of Neurology and Neuroscience, Peripheral Neuropathy Center, 635 Madison Avenue, Suite 400, New York, New York 10022, USA. THB2006@med.cornell.edu
Abstract:
Patients with multifocal motor neuropathy (MMN) respond to intravenous immune globulin (IVIg) and cyclophosphamide, although the benefit is not sustained. High-dose cyclophosphamide can induce a remission in patients with autoimmune diseases, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We describe a patient with refractory MMN who improved with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue. Following treatment she discontinued IVIg. At a 6-month examination, her strength had improved and she had regained the ability to write. High-dose cyclophosphamide may be a successful treatment for patients with MMN refractory to other therapies.